Fully integrated whole-body [18F]-fludeoxyglucose positron emission tomography/magnetic resonance imaging in therapy monitoring of giant cell arteritis

Eur Heart J. 2016 Feb 7;37(6):576. doi: 10.1093/eurheartj/ehv607. Epub 2015 Nov 9.

Authors

Ingo Einspieler¹, Klaus Thürmel², Matthias Eiber³

Affiliations

¹ Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Ismaningerstr. 22, Munich 81675, Germany [email protected].
² Department of Nephrology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.
³ Department of Nuclear Medicine, Klinikum rechts der Isar, Technische Universität München, Ismaningerstr. 22, Munich 81675, Germany.

PMID: 26553537
DOI: 10.1093/eurheartj/ehv607

No abstract available

Publication types

Case Reports

MeSH terms

Aged
Anti-Inflammatory Agents / therapeutic use
Drug Therapy, Combination
Fluorodeoxyglucose F18
Giant Cell Arteritis / drug therapy*
Giant Cell Arteritis / pathology
Glucocorticoids / therapeutic use
Humans
Magnetic Resonance Angiography / methods
Male
Methotrexate / therapeutic use
Multimodal Imaging / methods
Positron-Emission Tomography / methods
Radiopharmaceuticals

Substances

Anti-Inflammatory Agents
Glucocorticoids
Radiopharmaceuticals
Fluorodeoxyglucose F18
Methotrexate